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Abstract
Objective To determine whether use of metal-on-metal bearing surfaces
is associated with an increased risk of a diagnosis of cancer in the early
years after total hip replacement and specifically with an increase in
malignant melanoma and haematological, prostate, and renal tract
cancers.
Design Linkage study with multivariable competing risks flexible
parametric survival model to examine the incidence of new diagnoses
of cancer in patients with metal-on-metal hip replacement compared
with those with alternative bearings and to compare the observed
incidence of diagnoses in patients undergoing hip replacement with that
predicted by national incidence rates in the general population.
Setting National Joint Registry of England and Wales (NJR) linked to
NHS hospital episode statistics data.
Participants 40 576 patients with hip replacement with metal-on-metal
bearing surfaces and 248 995 with alternative bearings.
Main outcome measures Incidence of all cancers and incidence of
malignant melanoma and prostate, renal tract, and haematological
cancers.
Results The incidence of new diagnoses of cancer was low after hip
replacement (1.25% at one year, 95% confidence interval 1.21% to
1.30%) and lower than that predicted from the age and sex matched
normal population (1.65%, 1.60% to 1.70%). Compared with alternative
bearings, there was no evidence that metal-on-metal bearing surfaces
were associated with an increased risk of any cancer diagnosis in the
seven years after surgery (mean follow-up of three years, 23% (n=67
361) of patients observed for five years or more). Similarly, there was
no increase in the risk of malignant melanoma or haematological,
prostate, and renal tract cancers. The adjusted five year incidence of all
cancers for men aged 60 was 4.8% (4.4% to 5.3%) with resurfacing,
6.2% (5.7% to 6.7%) with stemmed metal-on-metal, and 6.7% (6.5% to
7.0%) for other bearing surfaces. Equivalent rates for women aged 60
were lower: 3.1% (2.8% to 3.4%) with resurfacing, 4.0% (3.7% to 4.3%)
with stemmed metal-on-metal, and 4.4% (4.2% to 4.5%) with other
bearings.
Conclusions These data are reassuring, but the findings are
observational with short follow-up. The use of hospital episode statistics
data might underestimate cancer diagnoses, and there is the possibility
of confounding by indication. Furthermore, as some cancers have a long
latency period it is important that we study the longer term outcomes
and continue to investigate the effects of exposure to orthopaedic metals.
Introduction
Metal-on-metal total hip replacement has become popular over
the past decade and now accounts for 35% of hip replacements
in the United States
1 and 14% of hip replacements recorded on
the National Joint Registry of England and Wales.
2 Of those
recordedontheNationalJointRegistry,abouthalfarestemmed
hip replacements and half are resurfacing procedures. Large
diameter metal-on-metal bearing surfaces have the potential
advantagesoflowerwear
3andlowerratesofdislocation.
4Recent
data from the National Joint Registry, however, has shown a
significantly higher failure rate with stemmed metal-on-metal
5
and an above average failure rate with hip resurfacing.
2 In
addition, little is known of the biological effects of the
metals—predominantly cobalt, chromium, and
molybdenum—thatarereleasedintothebodybytheseimplants.
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Research
RESEARCHAfter hip replacement, metal particles disseminate throughout
the body and can be found in many organs including marrow,
blood, liver, kidneys, and bladder.
6 7 Patients who have
undergone joint replacements have a higher than normal
incidence of DNA damage to blood lymphocytes.
8 In
concentrations found in the blood after hip replacement, cobalt
and chrome have the ability to signal across intact barriers in
the body and cause irreversible DNA changes to cells on the
other side of the barrier.
9 This calls into question the protective
ability of the placenta and blood-brain barrier.
A long history of occupational research has found that high
exposuretometalionsisassociatedwithanincreasedincidence
ofcertaincancers.
10Therefore,researchershavequeriedwhether
metal exposure from hip replacements could also lead to the
development of cancers. A 2006 meta-analysis found higher
rates of prostate cancer and melanomas in patients after hip
replacementthanamongthewiderpopulation.Italsofoundthat
the risk of renal tract cancers (affecting the bladder, ureter, and
kidney) increased over time for such patients, possibly through
urinaryexcretionofmetals.
11Furthermore,aSwedishstudyhas
shown that patients with osteoarthritis and rheumatoid arthritis
who have undergone knee replacement are at greater risk of
developingsomehaematologicalmalignanciesandarepossibly
at greater risk of developing prostate cancer and malignant
melanoma.
12
Detection of any increased risk of cancer requires a suitable
populationwithwhichtocomparepatientswithmetal-on-metal
articulations. Comparison with the general population is not
straightforward because, on average, patients who undergo hip
replacementtendtobehealthierthanothersofthesamesexand
age group. For instance, the National Joint Registry’s eighth
annual report found that observed mortality after joint
replacement was lower than that among the comparable wider
population.
2 Therefore, a more suitable comparison group is
patients with other types of hip replacement. We used the data
fromtheNationalJointRegistrylinkedtoNHShospitalepisodes
statistics data to test the hypothesis that the use of
metal-on-metalbearingsurfacesisassociatedwithanincreased
risk of being diagnosed with cancer in the early years after hip
replacement compared with other bearing surfaces.
Methods
Data sources
The National Joint Registry of England and Wales was
established in 2003 and is the largest arthroplasty database in
the world. It records all primary and revision hip and knee
replacementsundertakeninEnglandandWales,includingNHS
and independently funded operations. By April 2011, it
contained records of 1 082 465 procedures.
2 Coverage has
improved steadily since 2003 with 97% of orthopaedic units
submitting data in 2010. Data collection forms are completed
by surgeons at the time of operation and submitted by hospital
staff supported by regional coordinators. The hospital episode
statistics database is the primary source of NHS inpatient data
and contains details of all admissions to NHS hospitals in
England, including private patients treated in NHS hospitals,
patients who were living outside England, and care delivered
by treatment centres and private hospitals funded by the NHS.
Hospitalepisodestatisticsarebasedonmedicalrecordsassessed
by NHS clinical coding staff.
Every year, the National Joint Registry routinely links registry
dataandhospitalepisodestatisticsdatatocheckdataandtouse
thewiderhealthinformationinhospitalepisodestatisticsrelating
to joint replacement patients. As hospital episode statistics
contains details only on NHS funded admissions in England,
around 14% of National Joint Registry cases (relating to
independently funded operations in England and operations in
Wales) cannot be linked to hospital episode statistics. In
addition, 17% of joint registry records do not contain person
levelidentifiersthatallowlinkagetohospitalepisodestatistics,
usuallybecausethepatientdidnotgiveconsentfordatalinkage
and for their personal details to be held.
2 When data linkage
should be possible, 6% of registry hip replacements could not
be matched to hospital episode statistics. Characteristics of the
patientsthatcouldnotbematched(includingtheindependently
funded patients) were not dissimilar to those shown in table 1⇓
for linked patients (mean age 66.9, 42% men, mean American
Society of Anaesthesiologists (ASA) grade 1.8). We have used
the most recent linked data here: patients in England who
underwent hip replacement from 1 April 2003 to 31 December
2010andforwhomNationalJointRegistrydatacouldbelinked
to hospital episode statistics data (n=289 571).
Outcome measures
Hospital episode statistics data for all hospital admissions for
thesepatientsbetween1997(theearliesttimethatsuchdatacan
be obtained) and 2010 has been used and the relevant ICD-10
(internationalclassificationofdiseases,10threvision)diagnosis
codes have been used to define these conditions. This method
cannot precisely identify the time of diagnosis (as the initial
diagnosis might not have been associated with a hospital
admissioninthisperiod),butwhenthereweremultiplehospital
episodes for a patient, we chose the earliest date of any hospital
admission with the relevant diagnosis code.
We focused our main analysis on the risk of receiving a
diagnosis of any type of cancer in the years after hip
replacement, including all forms of cancer other than
non-melanoma skin cancers. The relevant ICD-10 codes are
C00-C97 (malignant neoplasms) and D00-D09 (carcinoma in
situ), excluding C44 (non-melanoma skin cancers). We also
individually considered some specific types of cancer that are
suspected of being related to metal ions, giving five sets of
analyses: any type of cancer, haematological cancers (such as
lymphoma, leukaemia, or myeloma), malignant melanoma,
prostatecancer(formenonly),andrenalcancer(bladder,ureter,
or kidney).
For each outcome, patients who had a recorded diagnosis of
that condition before, or at the time of, their hip replacement
were excluded from the analysis. These patients were not
excluded for the diagnosis of other cancers.
Statistical analysis
We compared patients with metal-on-metal hip replacements
(both stemmed hip replacements and resurfacing hip
arthroplasty) with two groups: the general population and
patientswithhipreplacementwithotherbearingsurfaces.Given
the large sample size, small differences can have P values of
less than 0.05
13 so for all analyses we present 95% confidence
intervals to indicate the range of any likely difference between
the groups.
Comparison with the general population
We used the Nelson-Aalen cumulative hazard function from
survival analysis to estimate unadjusted observed incidence
rates for a diagnosis of cancer after hip replacement. The
expected incidence is calculated by applying the age and sex
specific national cancer incidence rates (collated from cancer
registries and published by the Office for National Statistics
14)
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aPoissondistributiontocalculatethe95%confidenceintervals
for the expected rates.
Comparison with alternative bearing surfaces
We separated patients into three groups: those with stemmed
metal-on-metal, those with resurfacing arthroplasty, and total
hip replacements with other bearing surfaces. As the patients
areselectedforandnotrandomisedtodifferentsurgicaloptions,
we used multivariable analysis to adjust for the systematic
differences between groups of patients (table 1).⇓ In addition,
as we are observing a relatively elderly population, the risk of
death in the years after joint replacement is not insignificant
and ignoring it could bias the analysis.
2 To adjust for this
competing risk, we used a multivariable flexible parametric
survival model
15 to estimate the cumulative incidence of cancer
diagnosis in the presence of the competing risk of death.
16 This
method models the effect of the covariates both on the risk of
having a diagnosis of cancer (the main risk) and on the risk of
death (the competing risk). The effects of the covariates have
been allowed to vary for the main and competing risks. All
models control for the age and sex of the patient. In addition,
we used three proxy measures of general health at the time of
primary surgery. The first is the American Society of
Anaesthesiologists (ASA) grade, a measure of serious
comorbiditiesassessedbytheanaesthetistatthetimeofprimary
surgery and recorded in the National Joint Registry. Two other
measures were calculated from the hospital episode statistics
data: the number of distinct ICD-10 diagnosis codes recorded
at time of surgery (a proxy measure of the number of different
comorbidities) and the number of NHS funded admissions to
hospital in the previous five years (a proxy measure of health
status over time).
These models produce hazard ratios, which are a measure of
relative risk (averaged over time). To illustrate the absolute
effect of these factors, we used the models to predict incidence
ratesforatypicalpatientbyestimatingthecumulativeincidence
function adjusted for covariates in the presence of competing
risks. Values of covariates are held constant at factors around
the average (for the proxy measures of health) and by choosing
a value of age that has large enough numbers in all patient
groups to ensure robust estimation.
For the multivariable models, we assessed proportionality of
hazards by testing, for individual covariates and globally, the
nullhypothesisofzeroslope,whichisequivalenttotestingthat
theloghazardratiofunctionisconstantovertime.Log-logplots
were also assessed. We found no major violations of the
proportional hazards assumption. Model fit was assessed by
examiningtheCox-Snellresidualsanddevianceresiduals,which
indicated no outliers or any other cause for concern. We
undertook a sensitivity analysis to check whether clustering by
implant brand affected the results. The standard errors of a
standard Cox proportional hazards model were adjusted for the
clusteringbybrandtoallowforintragroupcorrelation.Thisdid
not significantly change the results, probably because many
brands of implants were used, particularly in stemmed
procedureswheredifferentcombinationsofstemsandcupscan
be used (there were 216 implant types that had been used in at
least 100 patients).
Results
Overall, 14% (40 576) of patients had some type of
metal-on-metal bearing surface: 7% (n=21 264) had a stemmed
metal-on-metalprosthesisand7%(n=19312)hadaresurfacing
procedure. The use of metal-on-metal has varied over time.
Resurfacing procedures formed 7% of all hip replacements in
2003 rising to 9% in 2005 and 2006 and falling to 3% by 2010.
Stemmed metal-on-metal formed just 2% of hip replacements
in 2003, rising to a peak of 11% in 2008, and falling to 4% in
2010. This increase in stemmed metal-on-metal was almost
entirely because of the use of large head sizes.
5 Table 1 shows
the sociodemographic characteristics of the three hip
replacement groups⇓. There were substantial differences
between the groups, with the resurfacing group in particular
being much younger and healthier than the other groups.
The mean length of time since surgery was 3.0 years (median
2.8 years) with 83% of patients having been observed for at
least one year and 23% for between five and eight years. Table
2 lists the diagnoses of cancers in this time period,⇓ and shows
that 1.25% of all patients were diagnosed with some type of
cancer within one year of their surgery. Annual incidence rates
tended to be similar with each additional year after surgery,
although they increased slightly as the patients became older.
Byfiveyears,8%hadhadadiagnosisofanytypeofcancerand
by seven years it was 11%. Diagnosis of the more specific
cancers was rarer (table 2)⇓.
Comparison with the general population
Basedonnationalcancerincidencerates,theexpectedoneyear
incidence of cancer for the hip replacement sample was 1.65%
(95% confidence interval 1.60% to 1.70%). A comparison of
one year observed diagnosis rates with expected rates showed
thatmenandwomenwithalltypesofhipreplacementwereless
likely to receive a diagnosis of cancer than an age and sex
matched general population (table 3⇓). Patients with
metal-on-metal bearing surfaces had lower observed incidence
rates than those with other bearing surfaces, with a particularly
low rate in younger patients in the resurfacing metal-on-metal
group.
Comparison with alternative bearing surfaces
Comparedwithothertypesofhipreplacement,themultivariable
statistical models found no evidence that having a stemmed
metal-on-metalhipreplacementoraresurfacingprocedurewas
associatedwithanincreasedriskofcancerdiagnosisinthistime
period(table4⇓).Thecompetingrisksmodelsalsoshowedthat
having a metal-on-metal bearing surface was not associated
with an increased risk of death (table 5⇓).
In fact, there was a suggestion of a slight decrease in the risk
ofanycancerdiagnosisassociatedwithmetal-on-metalbearing
surfaces. The models indicated that patients who underwent
resurfacing procedures were less likely than those with other
bearing surfaces to get a diagnosis of prostate cancer,
haematologicalcancers,oranycancer(table4⇓).Theyalsohad
a lower risk of death across all models than patients with other
bearingsurfaces(table5)⇓.Forstemmedmetal-on-metalbearing
surfaces, the hazard ratio for diagnosis of any type of cancer
was 0.92, but the 95% confidence interval was 0.85 to 1.00
suggesting that if there was any reduction in risk it was small.
Generally, the other factors in the model were significant
predictors of the risk of cancer diagnosis in all models (table
4)⇓. Increasing age was associated with an increased risk of
cancer diagnosis for all models. Men were more likely than
women to get a diagnosis of renal cancer, melanoma cancer,
haematologicalcancers,andanycancer.IncreasesinASAgrade,
numberofdiagnosiscodes,andnumberofpreviousadmissions
werealsopredictorsofanincreasedriskofcancerdiagnosisfor
allmodelsexceptformelanoma.Allofthesefactorswerestrong
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RESEARCHand significant predictors of the competing risk of death in all
models (table 5)⇓.
Table 6 shows adjusted incidence rates for any type of cancer
for a typical patient aged 60.⇓ This analysis shows a relatively
small reduction in the risk of cancer diagnosis for patients
undergoing resurfacing procedures, smaller than that observed
in the unadjusted analysis in table 3. Generally, the differences
between men and women are larger than those between the
groups with different types of hip replacement.
Discussion
Main findings
Despite the theoretical risks, we did not find a link between
metal-on-metalhipreplacements(eitherstemmedorresurfacing)
and increased incidence of cancer diagnosis. The incidence of
cancer diagnosis is low after hip replacement and is lower than
that predicted for the age and sex matched general population.
Furthermore, our models indicated that patients undergoing
resurfacing procedures were less likely than those with
alternative bearings to get a diagnosis of prostate cancer,
haematological cancers, or any cancer and had a lower risk of
death.
Strengths and weaknesses of the study
We analysed a large representative sample of patients with hip
replacement and so can have some confidence in the findings
for the period studied. Despite this confidence, we cannot
extrapolate these findings into the long term as some cancers
have a prolonged latency and thus will require an analysis of
long term data over the next few decades when these becomes
available.
The method of using data from hospital episode statistics to
identifycancerislikelytounderestimatediagnosesasaminority
ofpatientsmightreceiveadiagnosisandbetreatedwithoutany
inpatient admission. Such data also affect our ability to identify
theexacttimeofdiagnosis.Thereisnoreasontothink,however,
that the underestimation of cancer rates or that any uncertainty
around time of diagnosis will differ by the type of joint
replacement a patient had. Therefore, it is unlikely to affect the
overall comparison being made here between metal-on-metal
prostheses and other bearing surfaces. Registry data from other
countries confirms that patients’ demographics and disease
profiles are similar as are the implants used,
17 but incidences of
cancer do differ globally according to factors such as
environmental exposure, genetics, and lifestyle.
18 As such, the
extent to which these results are generalisable to healthcare
systemsoutsidetheUnitedKingdomwillvary.Hipreplacement
patients are not routinely screened for cancers. It is likely that
a targeted screening programme would identify more patients
with cancer than we have identified here. Furthermore, certain
at risk subgroups might be more susceptible to developing
cancer after exposure to these metals. The analysis reported
here would be unlikely to identify this unless the size of the
subgroup, or the magnitude of the effect, was large.
The difficulty of finding a suitable population with which to
compare patients with metal-on-metal articulations remains.
That the analysis found a reduced incidence of certain cancers
in patients with metal-on-metal bearing surfaces is not easy to
explain and could reflect a “well patient” effect and the
difficulties of adequately measuring and controlling for
differences in general health and wellbeing. In particular, the
comparisonbetweenpatientsundergoingresurfacingprocedures
and those with other bearing surfaces is not straightforward. As
well as undergoing a different surgical procedure, patients
undergoing resurfacing procedures tend to be much younger
and more active than other hip replacement patients and are
usually selected for the alternative resurfacing procedure for
precisely these reasons. Similarly, it is possible that there are
differences in the groups of patients who have stemmed
metal-on-metalprosthesesandthosewithotherbearingsurfaces,
resulting in confounding by indication.
While data from randomised controlled trials would be
preferable to observational data in terms of reducing
confounding, the sample sizes would not be large enough to
detect the relatively rare incidence of cancer. In addition, as all
joint replacements produce some metal debris, even if the
bearing surfaces are not metal, it would be prudent to compare
themwithacontrolgroupofpatientswithoutjointreplacements.
The control group would also need to have osteoarthritis as this
isassociatedwithlowerratesofcancer.
19Thiscomparisoncould
again be difficult because of a “well patient” effect as patients
who have undergone total joint replacement have been shown
tohavealowermortalityfromallcauses
2 20and,inthisanalysis,
a lower incidence of cancer than the general population. People
of lower socioeconomic status are less likely to be offered joint
replacement,
21 and lower socioeconomic status is associated
with cancer.
Comparison with existing literature
Visuri and colleagues performed a meta-analysis of studies
comparing the risk of developing cancer in patients with joint
replacements with the normal population and found a lower
risk.
22 We found the same. The meta-analysis by Onega and
colleaguescomparedtheincidenceof28cancersbetweenthose
receiving hip or knee replacement and the general population.
11
They found no increase in overall incidence of cancers, but an
increase in prostate cancer and malignant melanoma. The
increase in malignant melanoma became apparent only after 10
year follow-up. Occupational exposure to metals typically has
a long latency before the development of cancers.
23 As our
maximum follow-up was around seven years, we would not
detect cancers with a longer latency period. Visuri et al also
studied mortality after metal-on-metal and
metal-on-polyethylene hip replacement in a Finnish cohort of
2164 patients with over 16 years’ mean follow-up.
24 Although
both bearing surfaces were associated with lower overall
mortalitythanthenormalpopulation,thosewithmetal-on-metal
bearing surfaces had a higher mortality from cancer than those
with metal-on-polyethylene hips for the first 20 years after
surgery, but not thereafter. Because of our short follow-up we
have not considered mortality from cancer.
Some studies have shown an association between blood cobalt
and chromium concentrations and increased failure after
metal-on-metal hip replacements.
25 26 Cobalt and chrome have
been shown to be genotoxic, but it is unclear whether this is a
dosedependentorthresholdeffectanditisalsounclearwhether
cobalt and chrome work synergistically in producing
genotoxicity.
9 This work suggests that any genotoxicity is not
translated into an increase in cancers in the entire population in
the time period studied. At risk groups, however, such as those
with high serum concentrations of metal ions, warrant further
investigation.
Conclusions and implications for further
research
Therecentmediacoverageofmetal-on-metalhipreplacements
is likely to have increased fears among patients in England and
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RESEARCHWales with these implants, currently around 70 000 people.
Although these data are observational and we do not have long
termfollow-updata,theycanhelpclinicianstoreassurepatients
that the risk of cancer after hip replacement is relatively low
and that there is no evidence of an increase in cancer associated
with metal-on-metal bearing surfaces in the seven years after
surgery.Todeterminewhethermetal-on-metalhipreplacements
are associated with an increased risk of cancer in the long term,
however, we need more longitudinal data as well as more
researchtohelpdeterminethebiologicalconsequencesofmetal
exposureandtherebyprovideastrongtheoreticalbasistopredict
whichcancersmightarise.Wecanthenscreenforanypredicted
cancers. The analysis reported here will need to be repeated in
the future with a longer follow-up of the National Joint
Registry-hospitalepisodestatisticslinkeddata.Inthemeantime,
we need to link such data to the national cancer registries to
obtain a more complete picture of an evolving topic.
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RESEARCHWhat is already known on this topic
Metal-on-metal hip replacements produce metal particles that are disseminated throughout the body
Though these metal particles can cause DNA damage, there is no proved link between this and an increased incidence of cancer
Epidemiological studies are unclear as to whether metal-on-metal hip replacements are associated with an increase in cancers
What this study adds
In a large representative sample there was no association between metal-on-metal hip replacements and increased incidence of cancer
in the first seven years after hip replacement
The one year incidence of cancer after total hip replacement is lower than that observed in the general population
Tables
Table 1| Characteristics of patients undergoing hip replacement. Figures are percentages of patients unless stated otherwise
All hip replacement
(n=289 571)
Other bearing surfaces
(n=248 995)
Metal-on-metal
Stemmed (n=21 264) Resurfacing (n=19 312)
40 37 52 67 Men
60 63 48 33 Women
Age (years):
4 2 7 15 <45
8 6 15 35 45-54
23 20 35 41 55-64
36 38 30 8 65-74
25 29 12 0.4 75-84
5 5 2 0 ≥85
68.4 70.0 63.0 54.0 Mean age
ASA grade:
19 16 25 46 1-Fit and healthy
67 68 62 51 2-Mild systemic disease that does not limit activity
14 15 12 4 3-Systemic disease that limits activity but is not
incapacitating
1 1 1 0.1 4/5-Incapacitating, life threatening systemic disease/not
expected to survive 24 hours
2.0 2.0 1.6 1.9 Mean ASA grade
2.9 3.0 2.8 2.0 Mean No of distinct diagnosis codes at time of hip
replacement
3.5 3.7 3.3 2.3 Mean No of previous admissions to hospital
ASA=American Society of Anaesthesiologists.
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RESEARCHTable 2| Incidence rates (%) of new diagnosis of cancer for all patients who underwent hip replacement
Incidence rate (95% CI)
No with diagnosis Total time (years) observed No at risk
No excluded (previous
diagnosis) Five years One year
Stemmed metal-on-metal
5.65 (5.13 to 6.23) 1.00 (0.87 to 1.15) 653 58 338 20 186 1078 Any cancer
0.92 (0.72 to 1.17) 0.13 (0.09 to 0.19) 107 61 545 21 156 108 Haematological cancer
0.21 (0.13 to 0.33) 0.04 (0.02 to 0.08) 24 61 721 21 213 51 Malignant melanoma
1.92 (1.52 to 2.42) 0.35 (0.25 to 0.48) 117 30 435 10 786 185 Prostate cancer
0.53 (0.39 to 0.73) 0.12 (0.08 to 0.18) 67 61 558 21 160 104 Renal cancer
Resurfacing
3.34 (3.01 to 3.72) 0.50 (0.41 to 0.62) 445 69 358 18 940 372 Any cancer
0.41 (0.30 to 0.54) 0.05 (0.03 to 0.10) 55 71 131 19 266 46 Haematological cancer
0.12 (0.07 to 0.21) 0.02 (0.01 to 0.06) 20 71 253 19 284 28 Malignant melanoma
0.91 (0.71 to 1.16) 0.14 (0.09 to 0.22) 80 45 692 12 882 48 Prostate cancer
0.36 (0.26 to 0.49) 0.05 (0.03 to 0.10) 46 71 134 19 262 50 Renal cancer
Other bearing surfaces
8.17 (8.00 to 8.36) 1.34 (1.29 to 1.39) 10 845 686 500 232 215 16 780 Any cancer
1.31 (1.24 to 1.38) 0.21 (0.19 to 0.23) 1835 738 237 247 226 1769 Haematological cancer
0.28 (0.25 to 0.31) 0.05 (0.04 to 0.06) 415 741 432 248 273 722 Malignant melanoma
3.09 (2.91 to 3.27) 0.51 (0.47 to 0.57) 1558 261 665 88 737 2917 Prostate cancer
0.76 (0.71 to 0.81) 0.11 (0.10 to 0.14) 1088 737 004 246 937 2058 Renal cancer
All hip replacement
7.58 (7.42 to 7.74) 1.25 (1.21 to 1.30) 11 945 814 196 271 341 18 230 Any cancer
1.21 (1.15 to 1.27) 0.19 (0.18 to 0.21) 1997 870 914 287 648 1923 Haematological cancer
0.26 (0.23 to 0.29) 0.05 (0.04 to 0.06) 459 874 456 288 770 801 Malignant melanoma
2.68 (2.54 to 2.84) 0.45 (0.41 to 0.45) 1755 337 792 112 405 3153 Prostate cancer
0.71 (0.66 to 0.76) 0.11 (0.10 to 0.12) 1201 869 696 287 359 2212 Renal cancer
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RESEARCHTable 3| Comparison of expected and observed incidence rates (%) of cancer at one year for patients with hip replacement (with 95%
confidence intervals)
Observed incidence rate Expected incidence rate*
Women Men Women Men
1.11 (1.06 to 1.16) 1.46 (1.39 to 1.54) 1.48 (1.42 to 1.54) 1.91 (1.82 to 2.00) All hip replacement
0.84 (0.68 to 1.05) 1.15 (0.96 to 1.38) 1.22 (1.02 to 1.46) 1.45 (1.23 to 1.69) Stemmed metal-on-metal
0.56 (0.40 to 0.78) 0.48 (0.37 to 0.62) 0.73 (0.54 to 0.98) 0.77 (0.63 to 0.94) Resurfacing
1.15 (1.10 to 1.21) 1.66 (1.57 to 1.76) 1.53 (1.47 to 1.59) 2.13 (2.05 to 2.22) Other bearing surfaces
*Based on national incidence rates.
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RESEARCHTable 4| Results from multivariable flexible parametric competing risks survival models for main risk of cancer diagnosis
Renal cancer Prostate cancer Melanoma Haematological All cancers
P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) P value
Hazard ratio
(95% CI) Variable
<0.001 3.30 (2.93 to
3.72)
— — 0.005 1.31 (1.08 to
1.58)
<0.001 1.40 (1.28 to
1.53)
<0.001 1.57 (1.51 to
1.62)
Men
<0.001 1.05 (1.05 to
1.06)
<0.001 1.07 (1.06 to
1.07)
<0.001 1.03 (1.02 to
1.04)
<0.001 1.04 (1.03 to
1.04)
<0.001 1.04 (1.04 to
1.04)
Age
0.618 0.94 (0.73 to
1.21)
0.688 1.04 (0.86 to
1.26)
0.569 0.89 (0.58 to
1.35)
0.465 0.93 (0.76 to
1.13)
0.038 0.92 (0.85 to
1.00)
Stemmed
metal-on-metal
0.109 0.77 (0.57 to
1.06)
0.022 0.76 (0.60 to
0.96)
0.312 0.78 (0.48 to
1.26)
<0.001 0.58 (0.44 to
0.77)
<0.001 0.71 (0.64 to
0.78)
Resurfacing
0.016 0.81 (0.67 to
0.96)
0.501 1.05 (0.92 to
1.19)
0.472 0.91 (0.71 to
1.17)
0.041 0.87 (0.77 to
0.99)
<0.001 0.88 (0.84 to
0.93)
ASA 1 (v ASA
2)
0.704 1.03 (0.88 to
1.21)
0.050 1.14 (1.00 to
1.30)
0.129 0.80 (0.60 to
1.07)
0.026 1.14 (1.02 to
1.23)
0.006 1.07 (1.02 to
1.13)
ASA 3 (v ASA
2)
1.000 1.00 (0.53 to
1.87)
0.835 0.94 (0.54 to
1.64)
0.665 1.25 (0.46 to
3.38)
0.277 1.28 (0.82 to
2.00)
0.276 0.88 (0.70 to
1.11)
ASA 4-5 (v
ASA 2)
0.024 1.03 (1.00 to
1.06)
0.080 0.98 (0.95 to
1.00)
0.415 0.98 (0.93 to
1.03)
0.003 1.03 (1.01 to
1.06)
0.005 1.01 (1.00 to
1.02)
No of diagnosis
codes
0.004 1.02 (1.01 to
1.03)
0.011 1.01 (1.00 to
1.02)
0.043 1.02 (1.00 to
1.04)
<0.001 1.03 (1.02 to
1.03)
<0.001 1.02 (1.01 to
1.02)
No of previous
admissions
ASA=American Society of Anaesthesiologists.
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RESEARCHTable 5| Results from multivariable flexible parametric competing risks survival models for competing risk of death
Renal cancer Prostate cancer Melanoma Haematological All
Variable P value
Subhazard ratio
(95% CI) P value
Subhazard
ratio (95% CI) P value
Subhazardratio
(95% CI) P value
Subhazard ratio
(95% CI) P value
Subhazard
ratio (95% CI)
<0.001 1.38 (1.34 to
1.42)
— — <0.001 1.39 (1.35 to
1.43)
<0.001 1.41 (1.37 to
1.45)
<0.001 1.40 (1.35 to
1.46)
Men
<0.001 1.07 (1.07 to
1.08)
<0.001 1.07 (1.07 to
1.07)
<0.001 1.07 (1.07 to
1.08)
<0.001 1.08 (1.07 to
1.08)
<0.001 1.09 (1.09 to
1.10)
Age
0.169 0.95 (0.88 to
1.02)
<0.001 0.83 (0.76 to
0.89)
0.115 0.94 (0.88 to
1.01)
0.316 0.96 (0.89 to
1.04)
0.618 1.02 (0.93 to
1.12)
Stemmed
metal-on-metal
<0.001 0.55 (0.48 to
0.63)
<0.001 1.62 (1.53 to
1.71)
<0.001 0.55 (0.48 to
0.63)
<0.001 0.58 (0.51 to
0.67)
<0.001 0.72 (0.61 to
0.86)
Resurfacing
<0.001 0.83 (0.79 to
0.87)
0.968 1.00 (0.90 to
1.10)
<0.001 0.83 (0.79 to
0.88)
<0.001 0.83 (0.79 to
0.87)
<0.001 0.83 (0.78 to
0.89)
ASA 1 (v ASA
2)
<0.001 1.65 (1.60 to
1.71)
<0.001 0.56 (0.48 to
0.66))
<0.001 1.65 (1.60 to
1.71)
<0.001 1.66 (1.60 to
1.72)
<0.001 1.73 (1.65 to
1.80)
ASA 3 (v ASA
2)
<0.001 2.74 (2.50 to
3.01)
<0.001 2.62 (2.27 to
3.03)
<0.001 2.74 (2.51 to
3.01)
<0.001 2.66 (2.41 to
2.93)
<0.001 2.63 (2.34 to
2.96)
ASA 4-5 (v
ASA 2)
<0.001 1.11 (1.11 to
1.12)
<0.001 1.12 (1.12 to
1.13)
<0.001 1.11 (1.11 to
1.12)
<0.001 1.11 (1.11 to
1.12)
<0.001 1.12 (1.12 to
1.13)
No of diagnosis
codes
<0.001 1.04 (1.04 to
1.04)
<0.001 1.03 (1.03 to
1.04)
<0.001 1.04 (1.04 to
1.04)
<0.001 1.04 (1.04 to
1.04)
<0.001 1.04 (1.04 to
1.05)
No of previous
admissions
ASA=American Society of Anaesthesiologists.
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RESEARCHTable 6| Predicted cumulative incidence (%)* of cancer after hip replacement by bearing surface for typical patient aged 60
Year 5 Year 4 Year 3 Year 2 Year 1
Men
4.8 (4.4 to 5.3) 3.7 (3.4 to 4.1) 2.7 (2.5 to 2.9) 1.8 (1.6 to 1.9) 0.8 (0.7 to 0.9) Resurfacing
6.2 (5.7 to 6.7) 4.8 (4.5 to 5.2) 3.5 (3.3 to 3.8) 2.3 (2.1 to 2.5) 1.1 (0.9 to 1.2) Stemmed metal-on-metal
6.7 (6.5 to 7.0) 5.3 (5.1 to 5.5) 3.9 (3.7 to 4.0) 2.5 (2.4 to 2.6) 1.2 (1.1 to 1.2) Other bearing surfaces
Women
3.1 (2.8 to 3.4) 2.4 (2.2 to 2.6) 1.8 (1.6 to 1.9) 1.1 (1.0 to 1.2) 0.5 (0.5 to 0.6) Resurfacing
4.0 (3.7 to 4.3) 3.1 (2.9 to 3.4) 2.3 (2.1 to 2.5) 1.5 (1.4 to 1.6) 0.7 (0.6 to 0.7) Stemmed metal-on-metal
4.4 (4.2 to 4.5) 3.4 (3.3 to 3.5) 2.5 (2.4 to 2.6) 1.6 (1.5 to 1.7) 0.7 (0.7 to 0.8) Other bearing surfaces
*Results estimated from multivariable competing risks flexible parametric survival models based on 21 264 stemmed metal-on-metal cases, 19 312 resurfacing
procedures, and 248 995 hip replacements with other bearing surfaces. Values of model covariates are held constant at age 60, ASA grade of 2, two previous
admissions, and three diagnosis codes at admission.
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